Arcutis Appoints Patrick Burnett, M.D., Ph.D., FAAD, as Chief Medical Officer - Seite 3
Forward Looking Statements
This press release contains "forward-looking" statements, including, among others, statements regarding the potential and prospects of Arcutis and its product candidates, the timing of clinical
data readouts and the expectation that Dr. Welgus will serve as a member of the Board of Directors and that Dr. Burnett will serve as Chief Medical Officer. These statements involve substantial
known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from the information expressed
or implied by these forward-looking statements and you should not place undue reliance on our forward-looking statements. Risks and uncertainties that may cause our actual results to differ include
risks inherent in the clinical development process and regulatory approval process, the timing of regulatory filings, and our ability to defend our intellectual property. For a further description
of the risks and uncertainties applicable to our business, see the "Risk Factors" section of our Form 10-Q filed with U.S. Securities and Exchange Commission (SEC) on May 12, 2020, as well as any
subsequent filings with the SEC. We undertake no obligation to revise or update information herein to reflect events or circumstances in the future, even if new information becomes available.
Lesen Sie auch
Contact:
Heather Rowe Armstrong
Vice President, Investor Relations & Corporate Communications
harmstrong@arcutis.com
805-418-5006, Ext. 740